These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
507 related items for PubMed ID: 23488672
21. Pharmacokinetics and pharmacodynamics of the factor Xa inhibitor apixaban after oral and intravenous administration to cats. Myers JA, Wittenburg LA, Olver CS, Martinez CM, Bright JM. Am J Vet Res; 2015 Aug; 76(8):732-8. PubMed ID: 26207972 [Abstract] [Full Text] [Related]
22. Relative Bioavailability of Apixaban Solution or Crushed Tablet Formulations Administered by Mouth or Nasogastric Tube in Healthy Subjects. Song Y, Wang X, Perlstein I, Wang J, Badawy S, Frost C, LaCreta F. Clin Ther; 2015 Aug; 37(8):1703-12. PubMed ID: 26188837 [Abstract] [Full Text] [Related]
23. Population Pharmacokinetics, Pharmacodynamics, and Exploratory Exposure-Response Analyses of Apixaban in Subjects Treated for Venous Thromboembolism. Byon W, Sweeney K, Frost C, Boyd RA. CPT Pharmacometrics Syst Pharmacol; 2017 May; 6(5):340-349. PubMed ID: 28547774 [Abstract] [Full Text] [Related]
27. Apixaban: a new player in the anticoagulant class. Agrawal R, Jain P, Dikshit SN. Curr Drug Targets; 2012 Jun; 13(6):863-75. PubMed ID: 22250655 [Abstract] [Full Text] [Related]
28. Apixaban for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: The PAROS cross-sectional study of routine clinical practice. Falissard B, Picard F, Mahe I, Hanon O, Touzé E, Danchin N, Lamy FX, Ricci L, Steg PG. Arch Cardiovasc Dis; 2019 Jun; 112(6-7):400-409. PubMed ID: 31014991 [Abstract] [Full Text] [Related]
29. Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects. Wang X, Mondal S, Wang J, Tirucherai G, Zhang D, Boyd RA, Frost C. Am J Cardiovasc Drugs; 2014 Apr; 14(2):147-54. PubMed ID: 24277644 [Abstract] [Full Text] [Related]
30. Evaluation of safety, pharmacokinetics, and pharmacodynamics of apixaban in pediatric subjects at risk of venous or arterial thrombotic disorder. Merali SJ, Byon W, Patel YT, Elsrougy A, Marchisin D, Perera V, Chen W, He B, Murthy B. CPT Pharmacometrics Syst Pharmacol; 2023 Apr; 12(4):500-512. PubMed ID: 36861188 [Abstract] [Full Text] [Related]
34. Metabolism, pharmacokinetics and pharmacodynamics of the factor Xa inhibitor apixaban in rabbits. Zhang D, He K, Raghavan N, Wang L, Crain EJ, He B, Xin B, Luettgen JM, Wong PC. J Thromb Thrombolysis; 2010 Jan; 29(1):70-80. PubMed ID: 19851712 [Abstract] [Full Text] [Related]
35. Randomized, blinded, placebo- and positive-controlled crossover study to determine the effect of multiple doses of apixaban on the QTc interval. Frost C, Nepal S, Byon W, Moore K, Reeves RA, Boyd R, LaCreta F. J Clin Pharmacol; 2015 May; 55(5):549-55. PubMed ID: 25501868 [Abstract] [Full Text] [Related]
38. Population Pharmacokinetics and Pharmacodynamics of Apixaban Linking Its Plasma Concentration to Intrinsic Activated Coagulation Factor X Activity in Japanese Patients with Atrial Fibrillation. Ueshima S, Hira D, Tomitsuka C, Nomura M, Kimura Y, Yamane T, Tabuchi Y, Ozawa T, Itoh H, Horie M, Terada T, Katsura T. AAPS J; 2019 Jun 24; 21(5):80. PubMed ID: 31236790 [Abstract] [Full Text] [Related]